加载中
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
常规交易时段
US$9.40
−US$0.26 · -2.69%
盘中时间采用ET。市场数据可能有所延迟。
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
日内区间
当前US$9.40
52周区间
当前US$9.40
盘中时间采用ET。市场数据可能有所延迟。
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
日内区间
当前US$9.40
52周区间
当前US$9.40
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3203.2万 USD | 2518.2万 USD | 1603万 USD | 859.2万 USD | 545.1万 USD |
| 销货成本 | 424.4万 USD | 378.5万 USD | 280.4万 USD | 161.6万 USD | 138.5万 USD |
| 毛利 | 2778.8万 USD | 2139.7万 USD | 1322.6万 USD | 697.6万 USD | 406.6万 USD |
| 研究与开发 | 273.5万 USD | 236万 USD | 532.1万 USD | 552万 USD | 253.6万 USD |
| 销售、一般及管理费用 | 3820.6万 USD | 3119.9万 USD | 2671万 USD | 2433万 USD | 2157.3万 USD |
| 营业费用 | 4094.1万 USD | 3355.9万 USD | 3203.1万 USD | 2985万 USD | 2410.9万 USD |
| 利息收入 | 29.8万 USD | 57.2万 USD | 43.3万 USD | 28.7万 USD | 1.1万 USD |
| 利息支出 | 59万 USD | — | — | — | — |
| 折旧和摊销 | 167.5万 USD | 125.8万 USD | 102.5万 USD | 59.6万 USD | 38.2万 USD |
| 营业利润 | −1315.3万 USD | −1216.2万 USD | −1880.5万 USD | −2287.4万 USD | −2004.3万 USD |
| 净利润 | −1396.6万 USD | −1188.6万 USD | −1883.4万 USD | −2216.2万 USD | −1721.8万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年2月15日 | 1:15 | — | — |
已生效 2023年2月15日
1:15
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI133.52万0.00%2.3万亿 USD0.03%US$381.52-0.11%
Vanguard Extended Market ETFVXF64.91万0.00%954亿 USD0.05%US$233.92-0.46%
State Street SPDR S&P International Small Cap ETFGWX54.52万0.06%9.08亿 USD0.40%US$45.185-0.82%
iShares Micro-Cap ETFIWC18.68万0.01%13.17亿 USD0.60%US$181.96-0.57%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P International Small Cap ETFGWXiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
